Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Chemoembolization for hepatocellular carcinoma.

Lencioni R.

Semin Oncol. 2012 Aug;39(4):503-9. doi: 10.1053/j.seminoncol.2012.05.004. Review.

PMID:
22846867
2.

Chemoembolization in patients with hepatocellular carcinoma.

Lencioni R.

Liver Cancer. 2012 Jun;1(1):41-50. doi: 10.1159/000339019. Review.

3.

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J.

J Hepatol. 2012 Jun;56(6):1330-5. doi: 10.1016/j.jhep.2012.01.008. Epub 2012 Feb 5.

PMID:
22314428
4.

Chemoembolization of hepatocellular carcinoma.

Lencioni R, Petruzzi P, Crocetti L.

Semin Intervent Radiol. 2013 Mar;30(1):3-11. doi: 10.1055/s-0033-1333648. Review.

5.

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].

Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, B├╝chler MW, Jaeger D, von Kalle C, Schemmer P.

BMC Cancer. 2008 Nov 26;8:349. doi: 10.1186/1471-2407-8-349.

6.

Loco-regional treatment of hepatocellular carcinoma.

Lencioni R.

Hepatology. 2010 Aug;52(2):762-73. doi: 10.1002/hep.23725. Review.

PMID:
20564355
7.

Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective.

Takayasu K.

Oncology. 2011;81 Suppl 1:105-10. doi: 10.1159/000333269. Epub 2011 Dec 22. Retraction in: Takayasu K. Oncology. 2012;82(3):188.

8.

Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.

Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D.

Cardiovasc Intervent Radiol. 2010 Jun;33(3):541-51. doi: 10.1007/s00270-009-9750-0. Epub 2009 Nov 24.

PMID:
19937027
9.

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).

Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS.

J Surg Oncol. 2010 May 1;101(6):476-80. doi: 10.1002/jso.21522.

PMID:
20213741
10.

Chemoembolization of hepatocellular carcinoma--what to tell the skeptics: review and meta-analysis.

Ramsey DE, Geschwind JF.

Tech Vasc Interv Radiol. 2002 Sep;5(3):122-6. Review.

PMID:
12524642
11.

[Survival benefit with intraarterial techniques in hepatocellular carcinoma].

Sangro B.

Gastroenterol Hepatol. 2014 Jul;37 Suppl 2:95-101. doi: 10.1016/S0210-5705(14)70076-7. Spanish.

PMID:
25087719
12.

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R.

Cancer Treat Rev. 2011 May;37(3):212-20. doi: 10.1016/j.ctrv.2010.07.006. Epub 2010 Aug 17. Review.

PMID:
20724077
13.

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK.

Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25. Review.

PMID:
17103105
14.

Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.

Arabi M, BenMousa A, Bzeizi K, Garad F, Ahmed I, Al-Otaibi M.

Saudi J Gastroenterol. 2015 May-Jun;21(3):175-80. doi: 10.4103/1319-3767.157571. Erratum in: Saudi J Gastroenterol. 2015 Jul-Aug;21(4):264.

15.

A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST.

Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8. Epub 2007 Jul 12.

PMID:
17627902
16.

Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations.

Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF.

Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5. Epub 2011 Oct 19. Review.

17.

Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.

Matsui O.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:3-13. doi: 10.2165/1163021-S0-000000000-00000. Review.

PMID:
22873623
18.

Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective.

Takayasu K.

Oncology. 2013;84 Suppl 1:28-33. doi: 10.1159/000345886. Epub 2013 Feb 20.

PMID:
23428855
19.

Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects.

Lencioni R, Crocetti L, De Simone P, Filipponi F.

Transpl Int. 2010 Jul;23(7):698-703. doi: 10.1111/j.1432-2277.2010.01109.x. Epub 2010 May 14.

20.

Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Huang K, Zhou Q, Wang R, Cheng D, Ma Y.

J Gastroenterol Hepatol. 2014 May;29(5):920-5. doi: 10.1111/jgh.12439.

PMID:
24224722

Supplemental Content

Support Center